We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Health Catalyst (HCAT) Q4 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Health Catalyst (HCAT - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.10 per share, reflecting an increase of 150% compared to the same period last year. Revenues are forecasted to be $73.61 million, representing a year-over-year decrease of 7.5%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Health Catalyst metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenue- Professional services' stands at $22.88 million. The estimate points to a change of -18.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Technology' of $50.74 million. The estimate suggests a change of -1.7% year over year.
Analysts predict that the 'Adjusted Gross Profit- Professional Services' will reach $4.22 million. The estimate is in contrast to the year-ago figure of $3.78 million.
Based on the collective assessment of analysts, 'Adjusted Gross Profit- Technology' should arrive at $34.30 million. Compared to the present estimate, the company reported $33.35 million in the same quarter last year.
Over the past month, shares of Health Catalyst have returned -9.3% versus the Zacks S&P 500 composite's -2.7% change. Currently, HCAT carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Gear Up for Health Catalyst (HCAT) Q4 Earnings: Wall Street Estimates for Key Metrics
In its upcoming report, Health Catalyst (HCAT - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.10 per share, reflecting an increase of 150% compared to the same period last year. Revenues are forecasted to be $73.61 million, representing a year-over-year decrease of 7.5%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Health Catalyst metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenue- Professional services' stands at $22.88 million. The estimate points to a change of -18.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Technology' of $50.74 million. The estimate suggests a change of -1.7% year over year.
Analysts predict that the 'Adjusted Gross Profit- Professional Services' will reach $4.22 million. The estimate is in contrast to the year-ago figure of $3.78 million.
Based on the collective assessment of analysts, 'Adjusted Gross Profit- Technology' should arrive at $34.30 million. Compared to the present estimate, the company reported $33.35 million in the same quarter last year.
View all Key Company Metrics for Health Catalyst here>>>Over the past month, shares of Health Catalyst have returned -9.3% versus the Zacks S&P 500 composite's -2.7% change. Currently, HCAT carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .